Screener
Novavax NVAX Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| Cost reimbursements | $22.6M+249% | $27.72M+146% | $28.05M+222% | $45.83M+328% | $6.48M— | |
| Licensing, royalties, and other | $37.84M-83.4% | $97.31M+116% | $107.94M+271% | $57M+32.6% | $228.52M-41.8% | |
| Milestones amortization | $3.76M-33.6% | $5.55M-39.3% | $5.87M-14.4% | -$645K-109% | $5.67M+173% | |
| Milestones | $0-100% | —— | $50M— | $4.72M— | $175M— | |
| Royalties | $700K-86.0% | $3.52M— | $7.8M+271% | $4.2M-8.0% | $5M— | |
| Support services | $265K-4.7% | $100K— | $250K-57.1% | $272K-23.2% | $278K— | |
| Upfront fee amortization | $8.73M-28.9% | $12.11M-39.2% | $12.82M-13.4% | -$1.08M-107% | $12.27M+168% | |
| Upfront fee | $0-100% | —— | —— | $0-100% | $18.5M-95.2% | |
| Revenue from Contract with Customer, Excluding Assessed Tax by Geography | ||||||
| Canada | $0— | $0-100% | —— | $0— | $0— | |
| Europe | $1.12M-69.2% | $20.15M+149% | $3.37M+59.9% | $655K-63.9% | $3.63M+414% | |
| Rest of the world | $17.14M-54.2% | $23.28M-46.5% | $32.52M+76.4% | $13.01M+12.1% | $37.43M+84.6% | |
| United States | $38.44M-80.6% | $96.09M+144% | $111.24M+75.7% | $56.78M-20.1% | $198.18M-49.8% |
FAQ
- How does Novavax break its business down?
- Novavax (NVAX) reports total revenue by product across 8 parts — Cost reimbursements, Licensing, royalties, and other, Milestones amortization, Milestones and Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Novavax's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Novavax's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
